Latest Breaking News On - Taibao group - Page 1 : vimarsana.com

Published: Feb 24, 2021   Joint Venture Will Enable Cerus to Partner with Leader in Transfusion Medicine to Bring INTERCEPT to the Mainland China Transfusion Market   CONCORD, Calif. (BUSINESS WIRE) Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China. The JV, which will be named “Cerus ZBK Biomedical” (CEZB), will be headquartered in Zibo, Shandong Province in eastern China. “We are honored to join forces with ZBK in China, furthering our mission to make INTERCEPT the standard of care for patients globally,” said Pascal Maillard, Cerus’ vice president of commercial operations for the Asia Pacific region. “We believe that ZBK’s experience with local clinical and regulatory requirements, ISO-certified ma

United statesXu junfengPascal maillardExchange commissionCerus corporationShandong zhongbaokang medical implements coCerus corporation nasdaqShandong zhongbaokang medical implements co ltdTaibao groupShandong zhongbaokang medical implementsShandong provinceAsia pacificVirus inactivation plasma transfusion filtersLeukocyte removal filtersSterile infusion setsLiquid medicine filter